deltatrials
Completed OBSERVATIONAL NCT00539487

Observational Non-interventional Study (Anwendungsbeobachtung) With Telmisartan in High-risk Hypertensives

TOP -Study Telmisartan - Therapy of Hypertension and Life-style Changes in Cardiovascular Risk Patients

Sponsor: Boehringer Ingelheim

Updated 8 times since 2017 Last updated: Nov 7, 2013 Started: Jan 31, 2007 Primary completion: Nov 30, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Hypertension and Obesity and is currently completed. Boehringer Ingelheim leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Jan 2017 – ~Apr 2018 · 15 months · monthly snapshotCompleted~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshotCompleted~Nov 2025 – present · 8 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Nov 2025 — Present [monthly]

    Completed

  2. Sep 2025 — Nov 2025 [monthly]

    Completed

  3. Sep 2024 — Sep 2025 [monthly]

    Completed

  4. Jul 2024 — Sep 2024 [monthly]

    Completed

  5. Jan 2021 — Jul 2024 [monthly]

    Completed

Show 3 earlier versions
  1. Jun 2018 — Jan 2021 [monthly]

    Completed

  2. Apr 2018 — Jun 2018 [monthly]

    Completed

    Phase: NANone

  3. Jan 2017 — Apr 2018 [monthly]

    Completed NA

    First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .